Case reports of management of aplastic anemia after COVID-19 vaccination: a single institute experience in Taiwan

Int J Hematol. 2023 Jan;117(1):149-152. doi: 10.1007/s12185-022-03445-2. Epub 2022 Sep 4.

Abstract

Global vaccination against the coronavirus disease 2019 (COVID-19) is thought to be the most effective way to end or at least contain the COVID-19 pandemic. However, despite the good safety profiles and effectiveness of the available COVID-19 vaccines, rare but serious hematological complications have emerged, including thromboembolic outcomes with thrombocytopenia following the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) and Ad26.COV.2.S (Johnson & Johnson/Janssen) vaccines. Moreover, COVID-19 vaccination may be linked to the development of aplastic anemia (AA). We discuss four cases of AA that arose after COVID-19 vaccination in our hospital and two other such cases identified in our literature review.

Keywords: Aplastic anemia; COVID-19; Coronavirus disease 2019; SARS-CoV-2; Severe acute respiratory syndrome coronavirus-2 vaccine; Vaccination.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Anemia, Aplastic* / etiology
  • Anemia, Aplastic* / therapy
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • ChAdOx1 nCoV-19
  • Humans
  • Pandemics
  • Taiwan
  • Vaccination / adverse effects

Substances

  • ChAdOx1 nCoV-19
  • COVID-19 Vaccines